Literature DB >> 9713268

Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy.

H P Sinn1, H W Anton, A Magener, D von Fournier, G Bastert, H F Otto.   

Abstract

Intramammary tumour recurrence is one of the most important problems in breast-conserving therapy. We reviewed a series of 957 patients treated with breast-conserving therapy for primary invasive breast carcinomas between 1 January 1985 and 31 December 1992 at the University of Heidelberg. All histological slides were re-evaluated for risk factors with special emphasis on the extent and subclassification of the in situ tumour and the margin status. Six parameters were identified as significant risk factors for intramammary recurrence in the univariate analysis, including extensive or predominant in situ component (EIC, with at least twice the greatest dimension of the invasive tumour component), histological grade, angioinvasion, lobular tumour type, involved resection margin and lymph node status. The presence of an EIC was statistically correlated with low tumour grade, tumour at the resection margins and in re-excision specimens and with multifocal tumour invasion. Multivariate logistic regression analysis revealed that EIC (relative risk (RR) = 1.9), tumour grade (RR = 1.76), angioinvasion (RR = 1.34), lobular tumour type (RR = 1.65) and young age (< or = 40 years, RR = 1.39) were independent predictors of local recurrence. When combining these factors in a linear model, the simultaneous presence of at least two of the five risk factors predicted a 5-year risk of intramammary recurrence of 20.9% compared with a risk of only 1-5% when none or one of these risk factors were identifiable. We conclude that the risk of subsequent intramammary recurrence after breast-conserving therapy can be estimated from a scoring system that includes four histological risk factors and the patient's age.

Entities:  

Mesh:

Year:  1998        PMID: 9713268     DOI: 10.1016/s0959-8049(97)10106-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.

Authors:  Rainer Kuefer; Kathleen C Day; Celina G Kleer; Michael S Sabel; Matthias D Hofer; Sooryanarayana Varambally; Christoph S Zorn; Arul M Chinnaiyan; Mark A Rubin; Mark L Day
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

2.  [Update of the German S3 breast cancer guideline : What is new for pathologists?]

Authors:  A Lebeau; C Denkert; P Sinn; M Schmidt; A Wöckel
Journal:  Pathologe       Date:  2019-03       Impact factor: 1.011

3.  Ipsilateral breast tumor recurrence after breast-conserving therapy: A comparison of quadrantectomy versus lumpectomy at a single institution.

Authors:  Woo Chul Noh; Nam Sun Paik; Min Suk Kim; Kwang Mo Yang; Chul Koo Cho; Dong Wook Choi; Jong Inn Lee; Sung Ku Kang; Sang Bum Kim; Nan Mo Moon
Journal:  World J Surg       Date:  2005-08       Impact factor: 3.352

4.  c-myc amplifications in primary breast carcinomas and their local recurrences.

Authors:  S Aulmann; N Adler; J Rom; B Helmchen; P Schirmacher; H P Sinn
Journal:  J Clin Pathol       Date:  2006-02-23       Impact factor: 3.411

Review 5.  [Invasive breast cancer: the current WHO classification].

Authors:  A Lebeau; M Kriegsmann; E Burandt; H-P Sinn
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

6.  Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study.

Authors:  K Holli; R Saaristo; J Isola; H Joensuu; M Hakama
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

7.  Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis.

Authors:  San-Gang Wu; Wen-Wen Zhang; Jia-Yuan Sun; Zhen-Yu He
Journal:  Cancer Manag Res       Date:  2018-03-19       Impact factor: 3.989

8.  Evaluation of Breast Cancer Size Measurement by Computer-Aided Diagnosis (CAD) and a Radiologist on Breast MRI.

Authors:  Ji Yeon Park
Journal:  J Clin Med       Date:  2022-02-22       Impact factor: 4.241

9.  A machine learning ensemble approach for 5- and 10-year breast cancer invasive disease event classification.

Authors:  Raffaella Massafra; Maria Colomba Comes; Samantha Bove; Vittorio Didonna; Sergio Diotaiuti; Francesco Giotta; Agnese Latorre; Daniele La Forgia; Annalisa Nardone; Domenico Pomarico; Cosmo Maurizio Ressa; Alessandro Rizzo; Pasquale Tamborra; Alfredo Zito; Vito Lorusso; Annarita Fanizzi
Journal:  PLoS One       Date:  2022-09-19       Impact factor: 3.752

10.  Magnetic resonance imaging in size assessment of invasive breast carcinoma with an extensive intraductal component.

Authors:  Arjan P Schouten van der Velden; Carla Boetes; Peter Bult; Theo Wobbes
Journal:  BMC Med Imaging       Date:  2009-04-07       Impact factor: 1.930

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.